Viral Antigen Ingredients TRIZ Cases

Anti-HA antibodies target conserved hemagglutinin epitopes, overcoming viral mutation resistance and enabling broad-spectrum treatment.

Synthetic peptides conjugated with Poly IC form self-adjuvant complexes that generate antigen-specific CD8 T lymphocytes.

ALVAC vectors expressing AHSV VP2 and VP5 proteins eliminate vaccine reactions and reversion risks found in attenuated live virus vaccines.

Deleting the 9GL gene from ASFV-G creates an attenuated strain that protects pigs while enabling genetic differentiation of vaccinated animals.

A segmented polypeptide uses exogenous cathepsin cleavage sites to release specific peptide fragments that stimulate targeted immune responses.

Exposing tumor samples to gaseous nitric oxide followed by suspension and pH titration creates immunogenic vaccine candidates.

Segmented miRNA profiling identifies biomarker-positive patients, enabling precise VGX-3100 administration and avoiding unnecessary treatment.

Recombinant MVA vaccine maintains genetic stability during serial passage by segmenting antigens into independent loci and optimizing codons.

Neutral surfactants preserve Japanese encephalitis vaccine activity in microneedle arrays, preventing degradation during drying.

Substituting basic residues at the HPV11 L1 C-terminus resolves low expression and purification yield bottlenecks.

Anti-EBV antibodies bind the gH/gL heterodimer to neutralize viral entry, overcoming gp350 vaccine limitations.

A recombinant Pseudorabies virus expresses African swine fever virus proteins to induce protective antibodies in pigs.

Segmented HPV agonist epitopes targeting E6 and E7 oncoproteins enhance immune response precision while reducing vaccine development complexity.

E. coli strains overexpressing rare codons yield milligrams of self-assembling PCV-2 VLPs, while capture ELISA quantifies antigens without laborious detection.

A bivalent vaccine combines CMV envelope glycoprotein B and pentamer antigens to suppress congenital infection.

Modified vaccinia Ankara vector expresses the UL128 complex to stimulate neutralizing antibodies against human cytomegalovirus.

Recombinant chimeric antibodies target varicella-zoster virus glycoprotein H to neutralize viral particles and block cell-to-cell spread.

Sucrose and glycine stabilize rotavirus formulations, preventing potency loss during drying and storage.

Novel porcine parvovirus vaccine and specific PCR diagnostic tools target the infectious agent directly.

Specific genomic deletions and mutations in the novel MVA virus enable high-titer replication, reducing production time and costs while maintaining safety.

Fractionated pine cone extract enhances immune response while reducing toxicity to healthy cells.

Heparin affinity chromatography isolates biologically active Vaccinia virus from host cell DNA contaminants under mild elution conditions.

Uncleaved prefusion optimized gp140 trimeric complex generates neutralizing antibodies against broad HIV isolates.

A biopolymer scaffold compound with specific peptide sequences targets and sequesters undesirable antibodies in circulation.

Replacing AS01B with CpG 1018 TLR9 agonist maintains efficacy while reducing severe reactogenicity in herpes zoster vaccination.

DNA and viral vectors encoding HIV polypeptides induce targeted T-cell responses for durable viral control.

HERV-E antigen targeted CD8+ T cells eliminate renal cell carcinoma while reducing systemic toxicity.

GPI-anchored reactants tag membrane microvesicles and enveloped viruses for rapid purification without specific antibodies.

Using single-cell gene expression profiling to isolate cancer-reactive T cells from blood, bypassing invasive tumor resection.

Nucleic acid encoding HSV Fc receptor induces cross-reactive immune response against herpes simplex virus.

Inactivated MVA virus activates cytosolic DNA sensing to overcome tumor immune evasion and enhance checkpoint blockade efficacy.

Characterizing contemporary group 1 and 2 strains through S1 gene analysis resolves insufficient protection from historical vaccine isolates.

Chimpanzee adenovirus ChAd157 vectors utilize distinct fiber proteins to deliver transgenes while evading human immune recognition.

Segmenting the ASFV genome into conserved T-cell epitopes resolves vaccine development complexity while maintaining cross-genotype protection.

Modifying HBcAg mRNA and HBsAg phosphatidylserine levels in a hepatitis B vaccine overcomes limited seroconversion rates in chronic patients.

Co-local administration of adenovirus vectors and unadjuvanted HIV envelope polypeptides induces high-titer antibody responses.

Coexpressed L, M, and S proteins in CHO cells form VLPs that break immune tolerance and reduce viral antigen levels.

Differentiation-specific involucrin promoter drives viral envelope protein expression in epithelial stem cells for targeted mucosal delivery.

Double gene deletion of gE and TK creates an attenuated PRV strain with strong immunogenicity for livestock vaccination.

Modified parvovirus vaccine strains use targeted amino acid substitutions in the capsid protein to enhance immunogenicity.

Removing buffers from the rotavirus vaccine reduces dosage volume while maintaining stability against stomach acid.

Deacylated lipooligosaccharide adjuvant paired with HPV L1 virus-like particles resolves cytotoxicity and Th2 bias while inducing cellular immunity.

Removing specific N-linked glycans from HIV-1 envelopes eliminates steric hindrance, enabling broadly neutralizing antibodies to access the CD4 binding site.

VP1 virus-like particles paired with Toll-like receptor agonists overcome variable immune responses in Merkel cell carcinoma treatment.

Vitamin E and cholesterol modify squalene emulsions to reduce reactogenicity while maintaining immune efficacy in mRNA vaccines.

Targeting conserved CTL epitopes across HIV, SIV, and FIV induces robust cellular immune responses despite viral mutation pressures.

An inverse microlatex adjuvant stabilizes polymeric oily formulations, resolving phase separation issues while enabling direct sterilization.

A transgenic mouse expresses the human coxsackie group B virus receptor specifically in pancreatic beta cells.